Clinical trial

Colon cancer
#Cancer research #Cardiff Oncology #Clinical trial #Colorectal cancer #Oncology #Phase II trial

Metastatic colorectal cancer trial launches in the US

A Phase II trial to investigate onvansertib for the second line treatment of patients with KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) has treated its first patients. The ONSEMBLE trial is designed to demonstrate a clinically meaningful difference in response and onvansertib’s contribution to standard of care (SoC)… Read More

#Cancer Research #News

Blood tests in laboratory
#Clinical trial #Direct Biologics #Inflammatory Bowel Disease #Phase I trial

First patient dosed in ulcerative colitis drug trial

A Phase I clinical trial has begun evaluating Direct Biologics’ ExoFlo for the treatment of patients with medically refractory ulcerative colitis (UC). Direct Biologics uses extracellular vesicles (EVs) derived from bone marrow mesenchymal stem cells (MSCs) to address multiple disease indications. The trial is… Read More

#News

Atrial fibrillation
#Acesion Pharma #Cardiovascular disease #Clinical trial #Drug discovery #Phase II trial

Success for first new approach to atrial fibrillation for 20 years

The primary endpoint has been achieved in a Phase II trial of AP30663, a first-in-class SK ion channel inhibitor for conversion of atrial fibrillation (AF) to normal sinus rhythm. Acesion Pharma enrolled 63 patients with a current episode of AF in the trial and tested two… Read More

#News

#Clinical trial #CRISPR #FDA #Gene editing #Gene therapy #In vivo #Intellia Therapeutics

FDA clears in vivo gene editing therapy for trials in US

The US Food and Drug Administration (FDA) has cleared Intellia Therapeutics’ Investigational New Drug (IND) application for NTLA-2002 for the treatment of hereditary angioedema (HAE).  Intellia is a clinical-stage genome editing company focused on developing potentially curative therapies using CRISPR-based technologies.   The decision will enable the company to include the… Read More

#News #Regulatory #Trending News

Chronic gout
#Atom Bioscience #China #Clinical trial #Gout #hyperuricemia #Phase II trial

URAT1 inhibitor controls chronic gout at low doses

Atom Bioscience has revealed positive results from its China Phase IIa clinical trial of ABP-671, its URAT1 inhibitor for chronic gout.  The randomised, double-blind, placebo-controlled trial enrolled 54 patients with gout or  across six cohorts, with seven randomised to ABP-671 and two to placebo per cohort. … Read More

#News

NIHR Liverpool CRF - Main Bay
#Clinical research #Clinical trial #Laboratory #Liverpool #Phase I trial #Research & development

New clinical trial facility opens in Liverpool

The new Liverpool Clinical Research Facility (CRF) unit has opened at the new Royal Liverpool University Hospital thanks to £5.3m ($6.4m) funding from the National Institute for Health Research (NIHR).   The CRF will explore new treatments and vaccines for a range of diseases prevalent in Liverpool’s communities. This… Read More

#News

Degeneration of dopaminergic neuron
#Clinical trial #Neurology #Neuroscience #Newron Pharmaceuticals #Phase II trial #Schizophrenia

Evenamide could ‘open new treatment pathways’ for TRS

Newron Pharmaceuticals’ Evenamide could be a potential breakthrough treatment in the management of treatment-resistant schizophrenia (TRS) patients, according to new trial data.  The drug is being assessed as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe TRS who are not responding to… Read More

#Editor's Choice #News

MRI of the brain
#Clinical trial #Minoryx Therapeutics #Neurodegenerative disorders #Phase II trial

New treatment slows progression of neurodegenerative disease

Minoryx Therapeutics has revealed the findings from the first and largest international study to enroll adult male X-linked adrenoleukodystrophy patients.  The Phase II/III ADVANCE clinical trial of lead candidate, leriglitazone, published in The Lancet Neurology, did not meet the primary outcome… Read More

#News #Trending News

Woman tests blood glucose level
#Atrogi #Clinical trial #Diabetes #Phase I trial #Start-ups #Type 2 diabetes

Start-up hopes novel drug could treat cause of type 2 diabetes

Swedish start-up Atrogi has enrolled the first patient in its Phase Ia/b study of ATR-258, a novel b2adrenoceptor agonist for the treatment of type 2 diabetes and comorbidities.  Conducted in Mannheim, Germany by Clinical Research Services (CRS), the trial is expected to be completed by April 2023… Read More

#News #Start-up Zone

#Autoimmune disease #Cancer research #Clinical trial #Fibrosis #Immunotherapy #Oncology

First-line clinical trial marks a turning point in drug development 

Genoscience Pharma, a clinical-stage biotech company developing lysosomotropic drug candidates for the treatment of cancer, fibrosis and auto-immune diseases through autophagy modulation has launched the ABE-LIVER study, along with trial sponsor Grenoble University Hospital.  The trial   This Phase IIb clinical trial will focus on first-line… Read More

#Cancer Research #News

Year change from 2022 to 2023
#Clinical trial #Clinical trial design #Covid-19 #Drug delivery #Drug development #Healthcare

Drug discovery predictions: Analysis and insight 

In January 2022, DDW’s Megan Thomas spoke to decision-makers from the drug discovery industry about their predictions on what 2022 holds for our sector. As we head into 2023, DDW will be publishing a series of reflections on these predictions. Here, Thomas reflects specifically on Anita Cooper’s prediction relating to… Read More

#Exclusive Content #Opinion #Trends & Analysis

Pneumococcal disease vaccine
#Clinical trial #FDA #Immunology / Virology & Vaccines #Pneumonia #Regulatory #United States #Vaxcyte

Breakthrough Therapy designation for pneumococcal disease vaccine

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for VAX-24, Vaxcyte’s 24-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease.  The decision was based on positive topline results from a Phase I/II proof-of-concept study, which evaluated the safety, tolerability and immunogenicity of VAX-24 in… Read More

#News #Regulatory

Epidermolysis bullosa patient has foot bandaged
#Clinical trial #Dermatology #Epidermolysis bullosa #Gene delivery #Gene therapy

‘Life-changing’ topical gene therapy gel heals EB wounds

Researchers have found that a topical gene therapy gel helps heal wounds in patients with life-threatening blistering skin disease epidermolysis bullosa (EB).  People with dystrophic epidermolysis bullosa often suffer from large open wounds that last for years or decades. It’s an intensely painful condition, and medical treatment… Read More

#News #Trending News

Scientist in laboratory
#Cancer research #Cancer Research UK #Clinical trial #Genetic profiling #Rare cancers

Precision medicine study could find new options for rare cancers

Cancer Research UK, The University of Manchester and Roche have opened a multi-drug, precision medicine trial for people with rare cancers.  The trial is set up to recruit both paediatric and adult patients with any rare cancer type and is one of very few precision medicine platform… Read More

#Cancer Research #News

Shingles
#Clinical trial #GSK #Immunology / Virology & Vaccines #Recombinant Zoster Vaccine #Shingles

Shingles vaccine provides protection for a decade

New data have shown that GSK’s Shingrix provides at least 10 years of protection against shingles in adults aged 50 years and over. In the primary endpoint, the interim data demonstrated overall efficacy of greater than 80% over the follow-up period of approximately six to 10 years after initial vaccination. Read More

#News

#Biotechnology #Clinical trial #Liver disease

Clinical study first step towards treating respiratory syncytial virus 

Enanta Pharmaceuticals, a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, has dosed the first subject in its Phase I clinical trial of EDP-323, a novel, oral L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV).  Context … Read More

#News